Pharmaceutical Executive January 13, 2025
Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas.
With the start of the annual JP Morgan Healthcare Conference, several new deals have been announced by a number of pharma companies.
Already on Monday, Johnson & Johnson announced that it had reached an agreement to acquire Intra-Cellular Therapies for $14.6 billion, while GSK announced it had come to terms with IDRx to acquire the company for up to $1.15 billion.
Gilead
Gilead agreed to terms on a strategic partnership with LEO Pharma to accelerate the development and commercialization of STAT6, LEO’s small molecule oral program for treating patients with inflammatory diseases. Under terms of the deal, Gilead will...
Today's Sponsors
Today's Sponsor